Audrey Burban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Audrey Burban has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Sharanek
Univ. Bordeaux, Inserm, BRIC
4 shared publications - André Guillouzo
Inserm U991, Rennes, France
2 shared publications - Joris Guyon
INSERM, BRIC, UMR1312, University Bordeaux, Bordeaux, France
2 shared publications - Andreas Bikfalvi
BRIC INSERM U1312 Université de Bordeaux Pessac France
1 shared publication Antoine Italiano
Univ. Bordeaux, Inserm, BRIC
1 shared publication- Barbara Klink
MGZ – Medical Genetics Center, Munich, Germany
1 shared publication
Latest Publications
- Open Access
Development and validation of a LC-MS/MS method for ripretinib and its metabolite: example of a journey from laboratory bench to routine application with a greenness assessment
Therapeutic drug monitoring of protein kinase inhibitors is a widely practiced worldwide. Based on the example of ripretinib dosage requested by a clinician, we detailed the process of method development, using a literature-based approach while ensuring the sustainability of the method to be as environmentally friendly as possible. Therefore, an UPLC-MS/MS method for ripretinib and its active metabolite was optimized and validated using the corresponding stable isotopic internal standards in human plasma. The procedure has employed mobile phase mixture of water with 1% acetic acid and 0.1% formic acid, and acetonitrile. Positive electrospray ionization was performed coupling with multiple reaction monitoring of m/z 510.4→417.4 and 510.4→389.4 for ripretinib, and 496.3→403.3 and 496.3→375.3 for N-desmethyl-ripretinib. The method was successfully validated according the current version of ICH Guideline provided by the EMA. The greenness assessment score of this procedure was evaluated and compared with previously published approaches using the AGREE metric. The validated UPLC-MS/MS method successfully monitored ripretinib and its metabolite concentrations in clinical and pre-clinical models.
Open AccessDevelopment and validation of a LC-MS/MS method for ripretinib and its metabolite: example of a journey from laboratory bench to routine application with a greenness assessment
Therapeutic drug monitoring of protein kinase inhibitors is a widely practiced worldwide. Based on the example of ripretinib dosage requested by a clinician, we detailed the process of method development, using a literature-based approach while ensuring the sustainability of the method to be as environmentally friendly as possible. Therefore, an UPLC-MS/MS method for ripretinib and its active metabolite was optimized and validated using the corresponding stable isotopic internal standards in human plasma. The procedure has employed mobile phase mixture of water with 1% acetic acid and 0.1% formic acid, and acetonitrile. Positive electrospray ionization was performed coupling with multiple reaction monitoring of m/z 510.4→417.4 and 510.4→389.4 for ripretinib, and 496.3→403.3 and 496.3→375.3 for N-desmethyl-ripretinib. The method was successfully validated according the current version of ICH Guideline provided by the EMA. The greenness assessment score of this procedure was evaluated and compared with previously published approaches using the AGREE metric. The validated UPLC-MS/MS method successfully monitored ripretinib and its metabolite concentrations in clinical and pre-clinical models.
- Open Access
- 3 February 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (3) , 469-503
Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile
Glioblastoma is one of the most treatment-resistant and lethal cancers, with a subset of self-renewing brain tumour stem cells (BTSCs), driving therapy resistance and relapse. Here, we report that mubritinib effectively impairs BTSC stemness and growth. Mechanistically, bioenergetic assays and rescue experiments showed that mubritinib targets complex I of the electron transport chain, thereby impairing BTSC self-renewal and proliferation. Gene expression profiling and Western blot analysis revealed that mubritinib disrupts the AMPK/p27 Kip1 pathway, leading to cell-cycle impairment. By employing in vivo pharmacokinetic assays, we established that mubritinib crosses the blood-brain barrier. Using preclinical patient-derived and syngeneic models, we demonstrated that mubritinib delays glioblastoma progression and extends animal survival. Moreover, combining mubritinib with radiotherapy or chemotherapy offers survival advantage to animals. Notably, we showed that mubritinib alleviates hypoxia, thereby enhancing ROS generation, DNA damage, and apoptosis in tumours when combined with radiotherapy. Encouragingly, toxicological and behavioural studies revealed that mubritinib is well tolerated and spares normal cells. Our findings underscore the promising therapeutic potential of mubritinib, warranting its further exploration in clinic for glioblastoma therapy.
- 3 February 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (3) , 469-503
Open AccessExploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile
Glioblastoma is one of the most treatment-resistant and lethal cancers, with a subset of self-renewing brain tumour stem cells (BTSCs), driving therapy resistance and relapse. Here, we report that mubritinib effectively impairs BTSC stemness and growth. Mechanistically, bioenergetic assays and rescue experiments showed that mubritinib targets complex I of the electron transport chain, thereby impairing BTSC self-renewal and proliferation. Gene expression profiling and Western blot analysis revealed that mubritinib disrupts the AMPK/p27 Kip1 pathway, leading to cell-cycle impairment. By employing in vivo pharmacokinetic assays, we established that mubritinib crosses the blood-brain barrier. Using preclinical patient-derived and syngeneic models, we demonstrated that mubritinib delays glioblastoma progression and extends animal survival. Moreover, combining mubritinib with radiotherapy or chemotherapy offers survival advantage to animals. Notably, we showed that mubritinib alleviates hypoxia, thereby enhancing ROS generation, DNA damage, and apoptosis in tumours when combined with radiotherapy. Encouragingly, toxicological and behavioural studies revealed that mubritinib is well tolerated and spares normal cells. Our findings underscore the promising therapeutic potential of mubritinib, warranting its further exploration in clinic for glioblastoma therapy.
- 1 August 2019
- Published by Elsevier in Toxicology in Vitro
- Vol. 58, 51-59
Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic antibiotics
- 1 August 2019
- Published by Elsevier in Toxicology in Vitro
- Vol. 58, 51-59
Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic antibiotics
- Open Access
- 1 December 2017
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 45 (12) , 1292-1303
Progressive and Preferential Cellular Accumulation of Hydrophobic Bile Acids Induced by Cholestatic Drugs Is Associated with Inhibition of Their Amidation and Sulfation
Drug-induced intrahepatic cholestasis is characterized by cellular accumulation of bile acids (BA) whose mechanisms remain poorly understood. The present study aimed to analyze early and progressive alterations of BA profiles induced by cyclosporine A, chlorpromazine, troglitazone, tolcapone, trovafloxacin and tacrolimus after 4h, 24h and 6 daily treatments of differentiated HepaRG cells. In BA-free medium the potent cholestatic drugs, cyclosporine A, chlorpromazine and troglitazone, reduced endogenous BA synthesis after 24h, while the rarely cholestatic drugs, tolcapone, trovafloxacin and tacrolimus, reduced BA synthesis only after 6 days. In the presence of physiological serum BA concentrations, cyclosporine A, chlorpromazine and troglitazone induced early and preferential cellular accumulation of unconjugated lithocholic, deoxycholic and chenodeoxycholic acids that increased 8-12- and 47-50-fold after 24h and 6 days respectively. Accumulation of these hydrophobic BAs resulted from strong inhibition of amidation and in addition, for lithocholic acid reduction of its sulfo-conjugation, and was associated with variable alterations of uptake and efflux transporters. Trovafloxacin also caused BA accumulation, especially after 6 days, while tolcapone and tacrolimus were still without effect. However, when exogenous BAs were added to the medium at cholestatic serum concentrations, a 6-day treatment with all drugs resulted in cellular BA accumulation with higher folds of chenodeoxycholic and lithocholic acids. At the tested concentration, tolcapone had the lowest effect. These results bring the first demonstration that major cholestatic drugs can cause preferential and progressive in vitro cellular accumulation of unconjugated toxic hydrophobic BAs, and bring new insights in mechanisms involved in drug-induced cellular accumulation of toxic BAs.
- 1 December 2017
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 45 (12) , 1292-1303
Open AccessProgressive and Preferential Cellular Accumulation of Hydrophobic Bile Acids Induced by Cholestatic Drugs Is Associated with Inhibition of Their Amidation and Sulfation
Drug-induced intrahepatic cholestasis is characterized by cellular accumulation of bile acids (BA) whose mechanisms remain poorly understood. The present study aimed to analyze early and progressive alterations of BA profiles induced by cyclosporine A, chlorpromazine, troglitazone, tolcapone, trovafloxacin and tacrolimus after 4h, 24h and 6 daily treatments of differentiated HepaRG cells. In BA-free medium the potent cholestatic drugs, cyclosporine A, chlorpromazine and troglitazone, reduced endogenous BA synthesis after 24h, while the rarely cholestatic drugs, tolcapone, trovafloxacin and tacrolimus, reduced BA synthesis only after 6 days. In the presence of physiological serum BA concentrations, cyclosporine A, chlorpromazine and troglitazone induced early and preferential cellular accumulation of unconjugated lithocholic, deoxycholic and chenodeoxycholic acids that increased 8-12- and 47-50-fold after 24h and 6 days respectively. Accumulation of these hydrophobic BAs resulted from strong inhibition of amidation and in addition, for lithocholic acid reduction of its sulfo-conjugation, and was associated with variable alterations of uptake and efflux transporters. Trovafloxacin also caused BA accumulation, especially after 6 days, while tolcapone and tacrolimus were still without effect. However, when exogenous BAs were added to the medium at cholestatic serum concentrations, a 6-day treatment with all drugs resulted in cellular BA accumulation with higher folds of chenodeoxycholic and lithocholic acids. At the tested concentration, tolcapone had the lowest effect. These results bring the first demonstration that major cholestatic drugs can cause preferential and progressive in vitro cellular accumulation of unconjugated toxic hydrophobic BAs, and bring new insights in mechanisms involved in drug-induced cellular accumulation of toxic BAs.